Updated: 19 hours ago
When I told colleagues mid-way through my rather standard pharma career that I would move laterally into our emerging Digital Health function to a role, remit, and structure that was yet to be defined, I encountered a lot of well-meaning skepticism.
In their eyes, digital health is certainly seen as intriguing, but it carries a somewhat mixed reputation.
Despite its considerable hype and media omnipresence, there are only a small number of success stories out there, and tangible examples from big pharmaceutical enterprises are especially few and far between.
In this article I address some of the most prevalent concerns that big pharma holds with respect to digital health, and the implicit question behind: is this something worth persisting with?